Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057133 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2PPARALDHAXDHPPARG | |
| SCHEMBL27971306 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2PPARAPPARGHTTPTGDR2 | |
| SCHEMBL21057243 | 0.84 | PPARA (0.39) | PPARALDHAPPARGPTGDR2MEN1 | |
| SCHEMBL21057242 | 0.84 | PPARA (0.39) | PPARALDHAPPARGPTGDR2MEN1 | |
| SCHEMBL4812741 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2PPARAPPARGHTTPTGDR2 | |
| SCHEMBL4816920 | 0.84 | PPARA (0.59) | SMN1; SMN2PPARAPPARGHTTPTGDR2 | |
| SCHEMBL4817990 | 0.82 | PPARA (0.49) | SMN1; SMN2PPARAPPARGPTGDR2 | |
| SCHEMBL21057144 | 0.82 | PPARA (0.50) | SMN1; SMN2PPARAPPARGMEN1TSHR | |
| SCHEMBL21057134 | 0.82 | PPARA (0.49) | SMN1; SMN2PPARAPPARGPTGDR2 | |
| SCHEMBL4819977 | 0.82 | PPARA (0.50) | SMN1; SMN2PPARAPPARGMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723745-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | claimed |
| CN-111587109-A | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-08-25 | — | — | CN | claimed |
| WO-2019115777-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | claimed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | claimed |
| EP-3723745-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-06-19 | — | — | EP | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| EP-3723745-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2020-10-21 | — | — | EP | disclosed |
| CN-111587109-A | Phenoxy acids for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-08-25 | — | — | CN | disclosed |
| WO-2019115777-A1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | WO | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | SMN1; SMN2 13/4885PPARA 3247/4885LDHA 2645/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | SMN1; SMN2 13/4885PPARA 3247/4885LDHA 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.